Optimizing pharmacologic management of inflammatory bowel disease

Area of Science:

• Gastroenterology
• Pharmacology
• Immunology

Background:

• The expanding therapeutic options for Inflammatory Bowel Disease (IBD) necessitate a clear understanding of drug optimization and sequencing.
• Current treatment strategies involve aminosalicylates, corticosteroids, thiopurines, methotrexate, and biologics.

Purpose of the Study:

• To review dosing strategies and therapeutic drug monitoring for pharmacologic optimization in IBD.
• To guide clinicians in sequencing and optimizing individual and combination therapeutic approaches for IBD.

Main Methods:

• This is a review article summarizing existing literature on IBD pharmacologic optimization.
• Key areas covered include dosing, therapeutic drug monitoring, and sequencing of various IBD medications.

Main Results:

• Aminosalicylates are first-line for mild-to-moderate ulcerative colitis (UC) but less effective in Crohn's disease (CD).
• Budesonide and rectal corticosteroids offer alternatives; systemic steroids are effective but toxic.
• Thiopurines/methotrexate act as steroid-sparing agents; TNF inhibitors and newer biologics are crucial for moderate-to-severe IBD.

Conclusions:

• Personalized IBD treatment plans, considering disease location, phenotype, severity, and genetic factors, are essential for improved outcomes.
• Future IBD management should focus on targeted mechanisms of action and pharmacologic optimization for minimizing toxicity and therapeutic futility.